Quantum-Si (NASDAQ:QSI) Issues Earnings Results

Quantum-Si (NASDAQ:QSI) issued its earnings results on Thursday. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02, FiscalAI reports. The firm had revenue of $0.26 million during the quarter, compared to analyst estimates of $0.30 million. Quantum-Si had a negative net margin of 5,605.88% and a negative return on equity of 46.05%.

Here are the key takeaways from Quantum-Si’s conference call:

• Proteus reached a major technical milestone — Quantum-Si completed sequencing on fully integrated Proteus instruments detecting 17 amino acids and expects 18 by end-2026 with detection of all 20 during 2026 and a full sequencing kit in 2027, which management frames as a significant de‑risking versus Platinum.
• Early customer evaluations and commercial preparation look constructive — a prototype customer reported ~2x average read length and more amino acids detected versus Platinum, the company is running Proteus Roadshows and plans broader sample evaluations to build a buyer funnel, and has positioned Proteus at $425,000 versus >$1M for comparable high-end mass spec alternatives.
• Financial position supports the plan — Quantum‑Si had $190.4M in cash and investments at 3/31/26 and guides 2026 adjusted OpEx ≤ $98M and cash use ≤ $93M, projecting runway into Q2 2028 to fund Proteus completion and launch readiness.
• Near‑term revenue will remain limited — Q1 revenue was only $258k and the company reiterates 2026 revenue around ≈ $1M, describing 2026 as a transition year with modest capital sales as customers delay purchases pending Proteus availability.

Quantum-Si Price Performance

NASDAQ QSI traded down $0.07 during trading on Friday, reaching $0.91. The company’s stock had a trading volume of 13,112,028 shares, compared to its average volume of 6,228,345. The stock has a market capitalization of $196.16 million, a PE ratio of -1.78 and a beta of 3.15. The firm has a fifty day moving average of $0.90 and a 200 day moving average of $1.20. Quantum-Si has a one year low of $0.69 and a one year high of $3.10.

Analyst Upgrades and Downgrades

QSI has been the subject of a number of analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Quantum-Si in a research report on Friday, March 27th. Canaccord Genuity Group decreased their target price on shares of Quantum-Si from $1.50 to $1.00 and set a “hold” rating on the stock in a report on Wednesday, March 4th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Quantum-Si presently has an average rating of “Hold” and a consensus price target of $3.25.

Insiders Place Their Bets

In other Quantum-Si news, Director Paula Dowdy purchased 109,890 shares of the company’s stock in a transaction dated Thursday, March 5th. The stock was purchased at an average price of $0.95 per share, for a total transaction of $104,395.50. Following the transaction, the director owned 269,107 shares in the company, valued at $255,651.65. The trade was a 69.02% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Jeffrey Alan Hawkins sold 83,712 shares of Quantum-Si stock in a transaction dated Monday, April 20th. The shares were sold at an average price of $1.01, for a total value of $84,549.12. Following the sale, the chief executive officer owned 3,776,135 shares of the company’s stock, valued at approximately $3,813,896.35. This trade represents a 2.17% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 212,904 shares of company stock worth $205,021. Insiders own 22.04% of the company’s stock.

Institutional Investors Weigh In On Quantum-Si

Several hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC bought a new stake in Quantum-Si during the fourth quarter valued at approximately $262,000. Invesco Ltd. lifted its holdings in shares of Quantum-Si by 36.2% during the 4th quarter. Invesco Ltd. now owns 402,821 shares of the company’s stock worth $443,000 after acquiring an additional 107,093 shares during the last quarter. XTX Topco Ltd lifted its holdings in shares of Quantum-Si by 206.9% during the 4th quarter. XTX Topco Ltd now owns 461,982 shares of the company’s stock worth $508,000 after acquiring an additional 311,450 shares during the last quarter. Quadrature Capital Ltd bought a new stake in shares of Quantum-Si during the 4th quarter worth $305,000. Finally, Barclays PLC lifted its holdings in shares of Quantum-Si by 21.8% during the 4th quarter. Barclays PLC now owns 269,415 shares of the company’s stock worth $296,000 after acquiring an additional 48,205 shares during the last quarter. 39.90% of the stock is currently owned by institutional investors.

Quantum-Si Company Profile

Quantum-Si Inc is a life sciences instrumentation company headquartered in Guilford, Connecticut, developing next-generation proteomics solutions based on semiconductor sequencing technology. The company’s core offering centers on a proprietary single-molecule protein sequencing platform that uses a silicon-based sensor chip to convert protein data into digital signals. This approach is designed to deliver high sensitivity, single-amino-acid resolution and deep proteome coverage while potentially reducing cost and complexity compared to traditional mass spectrometry methods.

Quantum-Si’s product roadmap includes the development and commercialization of an integrated system comprising instruments, consumable reagents and proprietary data analysis software.